The treatment of ovarian cancer by a multimodality approach: Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation

A. Goldhirsch, R. Greiner, E. Dreher, G. Locher, B. W. Davis, J. P. Reinhard, R. Joss, K. W. Brunner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.

Original languageEnglish
Pages (from-to)383-387
Number of pages5
JournalOncology Research and Treatment
Volume8
Issue number6
DOIs
Publication statusPublished - 1985

Fingerprint

Remission Induction
Induction Chemotherapy
Altretamine
Ovarian Neoplasms
Melphalan
Radiation
Abdomen
Radiotherapy
Therapeutics
Carcinoma
Recurrence

Keywords

  • Chemotherapy
  • Ovarian cancer
  • RadiationReferences

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The treatment of ovarian cancer by a multimodality approach : Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation. / Goldhirsch, A.; Greiner, R.; Dreher, E.; Locher, G.; Davis, B. W.; Reinhard, J. P.; Joss, R.; Brunner, K. W.

In: Oncology Research and Treatment, Vol. 8, No. 6, 1985, p. 383-387.

Research output: Contribution to journalArticle

Goldhirsch, A. ; Greiner, R. ; Dreher, E. ; Locher, G. ; Davis, B. W. ; Reinhard, J. P. ; Joss, R. ; Brunner, K. W. / The treatment of ovarian cancer by a multimodality approach : Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation. In: Oncology Research and Treatment. 1985 ; Vol. 8, No. 6. pp. 383-387.
@article{62897e4247e74cbb94b35aa60394b288,
title = "The treatment of ovarian cancer by a multimodality approach: Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation",
abstract = "Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32{\%}) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.",
keywords = "Chemotherapy, Ovarian cancer, RadiationReferences",
author = "A. Goldhirsch and R. Greiner and E. Dreher and G. Locher and Davis, {B. W.} and Reinhard, {J. P.} and R. Joss and Brunner, {K. W.}",
year = "1985",
doi = "10.1159/000215691",
language = "English",
volume = "8",
pages = "383--387",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - The treatment of ovarian cancer by a multimodality approach

T2 - Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation

AU - Goldhirsch, A.

AU - Greiner, R.

AU - Dreher, E.

AU - Locher, G.

AU - Davis, B. W.

AU - Reinhard, J. P.

AU - Joss, R.

AU - Brunner, K. W.

PY - 1985

Y1 - 1985

N2 - Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.

AB - Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.

KW - Chemotherapy

KW - Ovarian cancer

KW - RadiationReferences

UR - http://www.scopus.com/inward/record.url?scp=0022403323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022403323&partnerID=8YFLogxK

U2 - 10.1159/000215691

DO - 10.1159/000215691

M3 - Article

C2 - 3937969

AN - SCOPUS:0022403323

VL - 8

SP - 383

EP - 387

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 6

ER -